Skip to main content
Smart Investors Daily
NE

NASDAQ · NERV

Minerva Neurosciences, Inc.

Healthcare · Biotechnology

$2.20

Down-$0.10 (-4.35%)

Updated Nov 17, 2026, 3:13 AM

SID Score

2.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.95M
P/E ratio
2.79
Dividend yield
0.00%
52-week range
$1.96 – $8.80
Volume
142.08K
Avg. volume
3.01M

Price performance · NERV

NERV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

NERV closed at $2.20 after 21 trading sessions, down 5.17% for the selected period.

Last close
$2.20
Period change
-5.17%
Period low
$2.20
Period high
$2.63
Daily close
View OHLC price history
NERV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$2.30$2.32$2.18$2.20142.08K
Nov 13, 2026$2.38$2.40$2.26$2.3074.57K
Nov 12, 2026$2.53$2.53$2.34$2.3879.4K
Nov 11, 2026$2.55$2.58$2.455$2.5695.7K
Nov 10, 2026$2.63$2.67$2.38$2.49110.86K
Nov 9, 2026$2.42$2.76$2.26$2.63348.31K
Nov 6, 2026$2.32$2.44$2.20$2.42238.04K
Nov 5, 2026$2.66$2.66$2.29$2.30182.09K
Nov 4, 2026$2.41$2.63$2.39$2.57308.64K
Nov 3, 2026$2.37$2.48$2.29$2.35240.55K
Nov 2, 2026$2.34$2.51$2.30$2.345230.6K
Oct 30, 2026$2.23$2.32$1.96$2.32394.69K
Oct 29, 2026$2.25$2.445$2.20$2.24267.56K
Oct 28, 2026$2.23$2.27$2.12$2.21204.4K
Oct 27, 2026$2.25$2.335$2.20$2.23239.28K
Oct 26, 2026$2.30$2.35$2.18$2.20173.15K
Oct 23, 2026$2.37$2.65$2.25$2.30137.59K
Oct 22, 2026$2.39$2.50$2.37$2.40121.14K
Oct 21, 2026$2.53$2.59$2.39$2.39102.62K
Oct 20, 2026$2.33$2.59$2.32$2.53194.28K
Oct 19, 2026$2.37$2.47$2.24$2.32118.34K

Latest NERV news

The latest Smart Investors Daily articles mentioning NERV.

NERV research

Overview

Company profile and research snapshot.

Company profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
NERV recent ratings
DateFirmRatingTarget
Aug 14, 2026JefferiesBuy—
Apr 15, 2026CitizensMarket Outperform—
Mar 12, 2026HC Wainwright & Co.Neutral—
Nov 6, 2025HC Wainwright & Co.Neutral—
Feb 26, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic science beyond dopaminergic mechanisms and to improve clinical trial methodology for negative symptoms Roluperidone remains the only late-stage drug candidate for this high-need population Company to host in-person and virtual KOL event on November 12, 2026 at 10:00 AM ET BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE)

Benzinga · Nov 6, 2026

Minerva Neurosciences Q3 EPS $(0.19) Beats $(0.21) Estimate

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 47.22 percent increase over losses of $(0.36) per share

Yahoo · Oct 29, 2026

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London. 2026 Jefferies Global Healthcare ConferenceDates: Monday, November 16 & Tuesday, November 17, 2026 Format: Fireside chat and 1x1 meetingsFireside Chat: Monday, Novemb

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.